Evaluate HM-002-1005 in Subjects With Type 2 Diabetes Mellitus
Summary
The purposes of this study are to: * Evaluate the safety and tolerability of the study drug. * Measure how much of the study drug (HM-002-1005) and its breakdown product get into the bloodstream, and how long it takes the body to get rid of them. * Measure the amount of glucose (blood sugar) and a substance called C-peptide in the bloodstream after receiving the study drug. Researchers will compare the study drug to a placebo (a look-alike substance that contains no drug). Participants will: * Stay 5 days and 4 nights or 6 days and 5 nights at the research site, and have a follow-up phone call 7 days after leaving the research site. * Take one (1) dose of the study drug or placebo * Have blood taken to measure the amount of study drug and its breakdown product and the levels of glucose and C-peptide * Have safety tests such as vital sign, ECGs, and glucose measurements
Timeline
- Start
- 2024-04-25
- Primary completion
- 2024-09-06
- Completion
- 2024-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HM-002-1005 | Unknown | 61.5 mg | Oral |
| Subject | HM-002-1005 | Unknown | 123 mg | Oral |
| Subject | HM-002-1005 | Unknown | 184.5 mg | Oral |
| Subject | HM-002-1005 | Unknown | 246 mg | Oral |
| Subject | HM-002-1005 | Unknown | 369 mg | Oral |